European Biosimilar Market to Reach €10.8 Billion by 2025, Comprising 44% of Generic Market.

Biosimilars are poised to significantly reshape the European generic drug market in the coming years. A recent analysis projects biosimilar sales will reach €10.8 billion by 2025 and comprise 44% of the overall generic market in Europe. This market shift is being driven by increasing adoption of these medications for treating complex diseases, including cancer, autoimmune disorders, and diabetes. The increasing availability of biosimilars, improved regulatory frameworks surrounding them, and growing awareness among healthcare professionals and patients are fueling this growth. This shift will impact the generic drug industry in Europe on multiple fronts. Increased competition is expected to drive down prices, ultimately improving patient access to more affordable treatments. Furthermore, companies are expected to focus on developing new biosimilars to capitalize on the expanding market.

Newsflash | Powered by GeneOnline AI
Date: April 14, 2025

Related posts:

Research: Drug Pricing Models Key to Pharma Success; Value Demonstration is Crucial Beyond Patent Expiration Generic Pharma Mergers Surge Amid Evolving Market Report: Strategic Patent Extensions Could Add Billions to Pharmaceutical Revenue Rocatinlimab Highlighted in GlobalData Analysis as Potential New Approach for Moderate-to-Severe Atopic Dermatitis Treatment

Author

Mark Chiang

紐約 NYU Computer Science 碩士 紐澤西 UMDNJ Biomedical Informatics 博士 中研院博士後 台灣大學博士後